Despite that statin treatment substantially reduces cardiovascular morbidity and mortality, many treated patients still experience a high residual risk. Statins lower LDL-cholesterol (LDL-C), with limited effects on other lipid parameters. Fibrates improve atherogenic dyslipidemia characterized by high triglyceride and/or low HDL-C levels and elevated concentrations of small dense LDL particles, with or without high LDL-C levels. Fibrates decrease cardiovascular morbidity especially in patients with the metabolic syndrome. The purpose of this review is to provide a rationale for the combined use of statins and fibrates in the management of patients with high residual cardiovascular risk related to atherogenic dyslipidemia and persisting after single therapy.
Introduction
An elevated low-density lipoprotein cholesterol (LDL-C) level is a major risk factor for cardiovascular disease (CVD), and several randomised clinical trials have shown that lowering LDL-C levels with statins results in a substantial reduced CVD morbidity and mortality [1,2 • ,3]. However, a significant number of treated patients continue to experience events, despite targeting LDL-C levels according to current guidelines [3, 4] . Moreover, even upon high doses of statins, a substantial residual risk remains [5, 6] .
Data from the INTERHEART study indicated that dyslipidemia is responsible for more than 50% of population-attributable vascular risk [7] . Within this context, more and more attention is now being paid to atherogenic dyslipidemia which is characterized by elevated triglyceride (TG) and low HDL-C levels, a preponderance of small, dense LDL particles, and an accumulation of cholesterol-rich remnant particles with high levels of apolipoprotein (apo) B.
These lipoprotein abnormalities are frequently found in patients with high vascular risk, including patients with the metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM) [8, 9] . Although the primary goal to reduce the cardiovascular risk in these patients is LDL-C lowering [10] , current treatment guidelines emphasize the relevance of considering the other lipoprotein abnormalities, but also non-lipid risk factors (such as tobacco consumption, blood pressure, physical activity, weight management….) that contribute to global risk [11, 12, 13] . Besides their effects on lipid metabolism, fibrates and statins display other pleiotropic effects, such as an improvement of endothelial function, a reduced inflammation at both vascular and systemic levels, an increased stability of atherosclerotic plaques, and a decreased thrombogenic response. Evidence suggests that, at least for statins, these pleiotropic effects may play a role in the reduction of cardiovascular morbidity and mortality [15, 16 •• ].
Pleiotropic effects of fenofibrate might explain the positive effects of fenofibrate on microvascular complications of T2DM, and a potential benefit on the CVD risk [17] .
However, whether combination statin-fibrate therapy is more effective on inflammatory markers than either form of monotherapy requires further investigation [18, 19] .
Patients treated with statins still experience a residual cardiovascular risk
A meta-analysis from 14 randomized secondary and/or primary prevention trials studied the efficacity of cholesterol-lowering therapy by statin therapy in patients with pre-existing coronary heart disease (CHD), history of diabetes or hypertension, i.e in a wide range of high- [3] . However, among the diabetic patients, the presence of low HDL-C and/or elevated TG limits the reduction in vascular events, even if patients achieve LDL-C levels below current targets [3] .
Intensive statin therapy with high-dose statins, resulting in LDL-C levels that are maximally reduced below currently optimal thresholds for treatment of very high-risk patients (i.e <70 mg/dL), provides an additional and significant cardiovascular benefit in patients with recent acute coronary syndromes (ACS) and stable CHD over standard-dose therapy [5, 6] . However, despite this, patients were still at very high residual risk, and although the combined analysis from 4 large trials yielded a 16% relative reduction of coronary death or any cardiovascular event (defined as MI, stroke, hospitalization for unstable angina, or revascularization) (p<0.0001), 28.8% of patients still experienced events [5] . More recently, pooled data from 6 trials, analysing separately recent ACS and stable CHD, showed that intensive statin therapy is associated with a reduction of 14 and 18% in cardiovascular death, ACS, or stroke, but is still leaving respectively 1 in 4 and 10 patients at risk, depending on their clinical subcategory [6] . Whether further increasing statin doses in monotherapy to further enhance LDL-C lowering is an appropriate strategy is a matter of debate for different reasons. First, because of the flattening of the dose-response curve at higher doses, the therapeutic benefit of dose increases likely becomes smaller, and recent data indicated that ACS patients with the lowest LDL-C levels have only modest clinical benefits after intensive statin therapy [20] . Second, increasing the statin dose occurs at the expense of increased risk for adverse events such as myalgia and/or elevations in liver or muscle enzymes. Third, the optimal target for LDL-C remains unknown and a large randomized trial is underway to examine whether the addition of ezetimibe to simvastatin, resulting in further decreased LDL-C as compared to changes 
Other lipoprotein parameters beyond LDL-C determine the CVD risk
Post-hoc analysis of 4S trial showed that patients with combined dyslipidemia at baseline, i.e elevated LDL-C, low HDL-C, and elevated TGs, had increased morbidity and an increased major coronary event (death, MI) rate on placebo [23] . Moreover, patients with T2DM experience higher rates of cardiovascular events with decreasing HDL-C and increasing TG concentrations, and an increasing LDL/HDL ratio [3] . Finally, retrospective analyses demonstrate that the achievement of combined lipid values, rather than solely reducing LDL-C, is associated with a reduced risk of cardiovascular events [24] .
The residual cardiovascular risk that remains after statin treatment is of multifactorial origin, and recent post-hoc analyses from clinical trials suggests an important contribution of lipid parameters other than LDL-C. It has long been established that HDL-C levels are a strong, independent inverse predictor of CVD [25] . Accordingly, post-hoc analyses showed that the inserm-00425686, version 1 -22 Oct 2009 risk of CVD events was inversely related to HDL-C levels in individuals with CVD who achieved LDL-C levels <70mg/dL upon statin treatment [26, 27] . A pooled analysis of 4 statin trials showed that a moderate increase in HDL-C (7.5%) correlated with atheroma regression [28] . Finally, from the BIP study, post-hoc extended analysis showed that HDL-C increments during bezafibrate therapy are inversely correlated with cardiovascular risk [29 • ], and longterm follow-up reported long-term reduction in mortality [30] .
Extensive evidence supports elevated TG levels, predominantly in the post-prandial state, as a predictor for CVD [31, 32] , and a recently published meta-analysis of 29 prospective studies ranging from a small decrease to essentially no changes or even a slight increase in highly hypertriglyceridemic patients. Moreover, fibrates increase LDL particle size and modify LDL subclass distribution from small, dense particles to large buoyant LDL particles, and reduce the number of small LDL particles in patients with hypertriglyceridemia and the MS [43, 44, 45] . In vivo kinetic experiments showed that atorvastatin or fenofibrate treatment of patients with T2DM or the MS and hypertriglyceridemia, results in a similar decrease of plasma TG levels probably due to comparable effects on VLDL-apoCIII kinetics [46] , and distinct but favourable effects on apoB-containing lipoproteins with apoB100 and apoB48 metabolism [47] . By contrast to atorvastatin, fenofibrate displayed significant effects on apoAI metabolism in HDL [48] . All these observations provide the rationale for the use of fibrate-statin combination therapy to optimally control dyslipoproteinemia in patients with T2DM or the MS.
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Fibrates reduce CVD in patients with atherogenic dyslipidemia
A number of angiographic and intervention trials have shown that fibrates can slow the progression of atherosclerotic disease and decrease CVD morbidity [14
••
]. However, most of the large prospective trials have been disappointing with respect to the primary endpoints, and meta-analysis suggest that fibrates do not influence overall mortality [49] . It is likely that these fibrate trials produced mixed results due to the large differences in study populations. with insulinemia in the highest fasting plasma insulin quartile benefited from a higher reduction in the RR for major cardiovascular events (a composite of CHD death, stroke, and non-fatal MI) than in the entire study population (RR of 32, 35 and 24% respectively) [51] after fibrate therapy. In the BIP study, bezafibrate treatment failed to achieve significance of the primary end point (a composite of fatal or non-fatal MI or sudden death) in patients with elevated LDL-C, low HDL-C and TG<150mg/dL. However, a post-hoc analysis showed significantly reduced event rates in patients with elevated TG levels [52] . More recently, a further post-hoc analysis confirmed that bezafibrate is more effective at reducing cardiovascular events among patients with the MS, with a more pronounced reduction in cardiac mortality depending on the number of MS features [53] . Finally, the FIELD study A recent post-hoc analysis of the BIP study using bezafibrate showed that in patients with low HDL-C and moderately elevated LDL-C, the clinical benefit of HDL-C and TG modification in terms of cardiac events (nonfatal MI or death) is inversely related with baseline levels of LDL-C, demonstrating enhanced benefit in patients with low LDL-C, whereas the benefit of LDL-C modification is more prominent in patients with increased LDL-C [54 • ]. Hence, combined assessment of LDL-C, HDL-C and TGs as therapeutic targets for lipid modification using lipid-lowering drugs may provide an incremental benefit on top of approaches based solely on LDL-C modification. Hence, a statin combination therapy with fibrates or other drugs that would enhance HDL-C and decrease TGs is recommended in such patients [10] .
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Short-term clinical studies have shown that combined therapy with statin and fenofibrate is more effective in controlling atherogenic dyslipidemia in patients with T2DM, the MS or combined dyslipidemia than the administration of either drug alone [18,55,56,57,58 • ].
Accordingly, it has been calculated that atorvastatin-fenofibrate combination therapy for 24
weeks to patients with T2DM, free of CVD at entry, would reduce the estimated risk for MI within the next 10 years from 21.6 to 4.2% [55] . Fenofibrate is an ester of fenofibric acid and requires first pass metabolism to form the active metabolite, fenofibric acid. ABT-335, the choline salt of fenofibric acid, is more hydrophilic than fenofibrate. This compound dissociates to form the free acid in the gastrointestinal tract, and fenofibric acid is rapidly tests the hypothesis whether, in the context of good glycemic control, adding fenofibrate to simvastatin will reduce the rate of CVD events compared to statin plus placebo.
Despite the potential benefit of fibrate statin combination therapy on the lipid profile, case reports of severe myopathy and rhabdomyolysis have raised concerns regarding safety of this coadministration. However, the absolute risk is low. Moreover, differences exist due to differences in pharmacokinetics and drug-drug interactions [63] . Pharmacokinetic data on the interactions between statins and fibrates suggest that gemfibrozil inhibits statin glucuronidation and its hepatic metabolism, inducing therefore higher statin concentrations, whereas other fibrates, such as fenofibrate, have a relatively low potential for interaction with statin metabolism [64] . Indeed, the combination of ABT-335 and rosuvastatin did not alter fenofibric acid pharmacokinetics, nor the rosuvastatin AUC, indicating that ABT-335 does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans [65] .
Hence, current guidelines recommend fenofibrate as the fibrate of choice for high-risk statintreated patients with atherogenic dyslipidemia [66] .
Conclusion and future perspectives
Although statins reduce cardiovascular morbidity and mortality owing, in part, to reduced LDL-C, a number of treated patients still face a very high cardiovascular risk. In fact, significant proportions of such patients are not reaching lipid goals. Generally they suffer from an atherogenic dyslipidemia associated to T2DM or the MS, which is not adequately corrected by statin therapy. Therefore, beyond a further decrease in LDL-C which could be achieved through the addition of other cholesterol-lowering agents, such as intestinal cholesterol absorption inhibitors (ezetimibe), other therapeutical approaches have to be developed for these dyslipidemic patients. Indeed, current guidelines recommend the addition of other drugs to achieve multiple lipid goals after LDL-C targets have been reached by statin therapy. Among these drugs, fibrates present a great interest because of its effects to reduce TG levels, improve LDL particle size and number, and increase HDL-C concentrations. Other 
